Panacea Biotec Shares Surge to 52-Week High

| Leave a Comment | Stocks

Panacea Biotec shares surged to a 52-week high of Rs 165 on September 18, buoyed by high-volume trade. Nearly one crore shares of the pharma company changed hands against a monthly average of 8 lakhs.

The sharp uptick in the stock price came after Dr Cyrus Poonawalla’s Serum Institute of India offloaded 4 lakh shares in the last trading session on September 15 at an average price of Rs 140.65. This is the second time in the ongoing quarter that Serum Institute has sold its shares in Panacea Biotec, having offloaded 5 lakh shares in August at an average price of Rs 146.31.

At the time of writing, the Panacea Biotec stock was quoting Rs 157.90 apiece on the NSE, up Rs 11.60, or 7.95 percent from the last close.

The company’s results for the April-June quarter were also positive, with revenue from operations increasing 16.21 percent year-on-year to Rs 129 crore and net profit rising to Rs 11 crore from a loss of Rs 56 crore in the same period last year.

Panacea Biotec is engaged in the business of pharmaceuticals and biotechnology, specialising in the development and manufacturing of vaccines and biosimilars, apart from antibiotics and other pharmaceutical formulations.


Related News

  • 22 Sep

    NBCC shares trade higher on Rs 100 crore work order from SAIL

    NBCC shares were trading 3 percent higher on September 22 after the company announced having bagged a work order worth Rs 100 crore from SAIL. This is the fourth order-win announced by the company in this month, the total value of the same being Rs 450 crore. NBCC is a public sector undertaking engaged in the business of construction and real estate development. The company specializes in providing project management, consultancy and engineering services for civil construction, infrastructure development, and real estate projects.

  • 22 Sep

    Glenmark Pharma stock falls on stake sale in Glenmark Life Sciences

    Glenmark Pharma stock fell after the company announced it would sell a 75% stake in its subsidiary Glenmark Life Sciences to Nirma. Analysts expect the stake sale to benefit Glenmark Pharma, as it will transition from a net debt position to a cash surplus position. This is expected to have a positive impact on the company's return ratios over the next two to three years.

  • 22 Sep

    Berger Paints Shares Hit 52-Week High After Turning Ex-Bonus

    Berger Paints shares surged 6% to hit a 52-week high after turning ex-bonus on the record date for the issue of bonus shares in the ratio 1:5. The company posted a net profit of Rs 326.3 crore in the April-June quarter of FY24, up 39% year-on-year, on revenue of Rs 2,739.7 crore, up 10% year-on-year. The company expects to get net cash positive by the end of this fiscal year and expects to end the year with double-digit revenue growth on strong demand outlook.

  • 22 Sep

    Market Update for September 22, 2023

    IdeaForge Tech up 3.4% on order RVNL up 3% on highway MoU JSW Steel up 0.4% on sale ICICI Lombard down 1.6% on CEO exit ICICI Bank down 1% on healthcare investment NHPC up 1.3% on extended additional charge Kalyani Forge up 3.2% on new MD IRB Infra up 2.5% on road project closure

  • 22 Sep

    Lux Industries Shares Down 3% After Income Tax Raid

    Lux Industries shares fell 3% on September 22 after news emerged that the Income Tax department had conducted searches at the company's premises in Kolkata and alleged a tax evasion of Rs 200 crore. The company has confirmed the searches and is extending full support.

Leave a Reply

Your email address will not be published. Required fields are marked *